Search - tctmd.com

Displaying 321 - 340 of 362

Sort: Relevancy | Date

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

L.A. McKeown

July 29, 2015

Presentation

Impact of Dual Lipid Lowering With Ezetimibe and Atorvastatin on Plaque Regression in PCI Patients

Presenter: K. Tsujita

July 28, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

Recommendations Tackle Hypertension in CAD Patients

Todd Neale

April 03, 2015

News Conference News AHA 2014

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

November 16, 2014

Presentation TCT 2014

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran

September 15, 2014

Presentation TCT 2014

Intravenous HDL to Regress Plaque

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran

September 15, 2014

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

News Industry News

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

August 25, 2014

News Daily News

Cardiac Troponin T Threshold Predicts Mortality After PCI

August 20, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Daily News

Long-term Mortality Worse for Black vs White NSTEMI Patients, Linked with Treatment Discrepancies

July 17, 2014

News Industry News

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

June 11, 2014

News Daily News

PROSPECT Substudy: Persistently High CRP Predicts Future MACE in ACS Patients After PCI

June 04, 2014

News Daily News

Clinical Outcomes of Carotid Stenting Comparable in Radiation-Induced and Atherosclerotic Stenoses

L.A. McKeown

April 11, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Daily News

Statins Reduce Amputations After Lower Extremity Procedures

Jason Kahn

December 30, 2013

Advertisement

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

Impact of Dual Lipid Lowering With Ezetimibe and Atorvastatin on Plaque Regression in PCI Patients

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Recommendations Tackle Hypertension in CAD Patients

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Intravenous HDL to Regress Plaque

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

Cardiac Troponin T Threshold Predicts Mortality After PCI

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Long-term Mortality Worse for Black vs White NSTEMI Patients, Linked with Treatment Discrepancies

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

PROSPECT Substudy: Persistently High CRP Predicts Future MACE in ACS Patients After PCI

Clinical Outcomes of Carotid Stenting Comparable in Radiation-Induced and Atherosclerotic Stenoses

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

Statins Reduce Amputations After Lower Extremity Procedures

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content